Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 3;14:111. doi: 10.1186/s12967-016-0861-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Owonikoko et al. 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — Efficacy of ASO (3.75 mg/kg i.p. every other day) and cisplatin (3 mg/kg i.p. weekly) was tested in TKO-002, a PDX model of platinum refractory SCLC. Tumor volume (mm³) and body weight of animals were measured at least twice weekly while on treatment. There was no significant tumor growth inhibition by ASO (*p = 0.48) or cisplatin (**p = 0.42) in comparison to vehicle-treated control animals at the end of the treatment period (top). There was also no significant difference in the harvested tumor weights from animals treated with ASO compared to control animals treated with vehicle (*p = 0.33) (middle). There was no significant increase in toxicity (measured by body weight of the animals) with active therapy in comparison to controls (bottom)